{"entity":{"id":"caroline-dive","kind":"person","name":"Caroline Dive","aka":[],"tldr":"Built small-cell lung cancer models from circulating tumour cells and leads the Manchester institute.","summary":"Caroline Dive is Director of the Cancer Research UK Manchester Institute and Professor of Cancer Pharmacology, working with The Christie NHS Foundation Trust and Cancer Research UK. Her specialisms are liquid biopsy, circulating tumour cells and small-cell lung cancer models. She pioneered explant models of small-cell lung cancer grown from patients' circulating tumour cells, reported in Nature Medicine as a study of the tumorigenicity and genetic profiles of those cells. She now leads the Manchester institute and its biomarker centre, working across circulating tumour DNA and patient-derived xenografts. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dive%20C%5BAuthor%5D%20circulating%20tumour%20cells%20small%20cell"}],"tags":[],"related":[],"cancers":["sclc"],"sections":[],"technologies":["liquid-biopsy","pdx-models"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie","cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Research UK Manchester Institute; Professor of Cancer Pharmacology","institutionId":"the-christie","specialisms":["Liquid biopsy","Circulating tumour cells","Small-cell lung cancer models"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dive%20C%5BAuthor%5D%20circulating%20tumour%20cells%20small%20cell"}],"papers":[{"title":"Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer","journal":"Nature Medicine","year":2014,"doi":"10.1038/nm.3600"}],"orcid":"0000-0002-1726-8850"},"route":"/people/caroline-dive/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/"},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/"}],"idea":[{"id":"idea-bio2-ctc-clearance-go-nogo","kind":"idea","name":"Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs","route":"/ideas/idea-bio2-ctc-clearance-go-nogo/"},{"id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/"}],"trial":[{"id":"target-national","kind":"trial","name":"TARGET National","route":"/trials/target-national/"}]}}